Back to Search Start Over

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.

Authors :
Chu, Yurou
Zhou, Xiangxiang
Wang, Xin
Source :
Journal of Hematology & Oncology; 6/5/2021, Vol. 14 Issue 1, p1-20, 20p
Publication Year :
2021

Abstract

Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic drugs. ADCs comprise monoclonal antibodies, cytotoxic payloads with inherent antitumor activity, and specialized linkers connecting the two. In recent years, three ADCs, brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine, have been approved and are already establishing their place in lymphoma treatment. As the efficacy and safety of ADCs have moved in synchrony with advances in their design, a plethora of novel ADCs have garnered growing interest as treatments. In this review, we provide an overview of the essential elements of ADC strategies in lymphoma and elucidate the up-to-date progress, current challenges, and novel targets of ADCs in this rapidly evolving field. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17568722
Volume :
14
Issue :
1
Database :
Complementary Index
Journal :
Journal of Hematology & Oncology
Publication Type :
Academic Journal
Accession number :
150714170
Full Text :
https://doi.org/10.1186/s13045-021-01097-z